# Syncona Limited Delivered excellent financial and operational performance

- Link: https://www.directorstalkinterviews.com/syncona-limited-delivered-excellent-financial-and-operational-performance/412761794
- Published: 2018-11-21T07:41:22+00:00
- Author: Charlotte Edwards

**Syncona Limited** (LON:SYNC), today announced Interim Results for the six months
ended 30 September 2018.

**Life science companies continue to drive strong returns and increase in NAV**

· Net assets at 30 September 2018 of £1,394.0 million; 208.1p[1] per share, a total
return of 32.5 per cent[2]

· Life science portfolio, valued at £945.7 million (68 per cent of net assets), 
a 62.6[3] per cent return over the six months

· £94.3m net investment into life science during the half year; expect investment
for the financial year to be at the top end of guidance of £75 million to £150 million

· Capital pool[4] supporting life science investment of £448.3 million (cash of 
£41.8[5] million and fund investments of £406.5 million)

**Excellent financial and operational performance**

· Blue Earth Diagnostics (Blue Earth), our PET imaging agent company, valuation 
increased by £44.8 million as the business continues to make strong progress following
its move into profitability, with over 28,000 patients dosed since launch in late
2016 and £35.0 million of revenues during the six months, up from £23.5 million 
in the prior six month period

· Autolus, our T cell immunotherapy company, completed a $172.2 million IPO on NASDAQ
in June 2018, with Syncona investing $24.0 million, retaining a 32.7 per cent stake,
which was valued at £319.9 million at 30 September, a gain of £216.7 million over
the six months

· £68.7 million increase in our holding in Nightstar, our gene therapy company targeting
inherited forms of blindness following a 43% appreciation of its share price. The
business raised $82.0 million in a placement of shares in September 2018. Syncona
invested $18.0 million in the share placing, retaining a 38.3 per cent stake in 
the business, in line with our strategy of supporting our companies over the long-
term

· In June 2018 we announced an £85.0 million Series B financing commitment by Syncona
to Freeline, our gene therapy company focused on liver expression for chronic systemic
diseases; and have an 80% stake in the business

· £9.8 million new commitment to OMass Therapeutics in a £14.0 million Series A 
financing. OMass is a biopharmaceutical company using structural mass spectrometry
to discover novel medicines which Syncona believes represents a unique platform 
to transition to therapeutic development.

**Strong clinical progress across our companies**

· Post period end, Freeline reported initial positive data from the first two patients
in its Phase 1/2 trial in Haemophilia B. Professor Amit Nathwani will present results
from this trial at the annual meeting of the American Society of Haematology (ASH)
in December 2018

· Autolus also announced that it will present one oral and two poster presentations
related to its AUTO3 and AUTO5 programs at ASH

· Nightstar reported positive proof-of-concept data in its Phase 1/2 trial in XLRP.
Its pivotal trial in Choroideremia commenced during the period, with the company
also receiving Regenerative Medicine Advanced Therapy (RMAT) Designation from the
FDA, an expedited programme for the advancement and approval of products

**Outlook – continued momentum across our companies and rich opportunity for further
investments**

We enter the second half with strong momentum across our portfolio. Our companies
continue to advance their business plans, strong pipeline of clinical programmes
and preclinical product candidates. We believe they are well placed to continue 
to execute their clinical and regulatory processes, although such processes are 
not without risk.

We have a high-level of conviction in the fundamentals of our companies and are 
focused on working with them closely. As we have done over the first half with Nightstar,
Autolus and Freeline, we expect to continue to fund our companies through the next
stages of their development cycle.

We now have a portfolio of nine companies, eight of which were founded by Syncona.
We continue to see exciting new opportunities in cell and gene therapy, an area 
where we are strategically positioned with a leading platform and deep domain expertise.
We believe that the arrival of this new wave of therapies is an important technological
shift and will provide the potential to treat previously intractable diseases. We
also continue to evaluate opportunities more broadly across a range of therapeutic
areas and modalities where we believe we can found, build and fund companies around
exceptional science in areas of high unmet medical need and support these companies
through their development cycle with the ultimate goal of delivering transformational
treatments to patients.

As we look forward, we expect investment to be at the top end of our guidance of
£75 million to £150 million in this financial year as we continue to fund our existing
companies and add new companies to our portfolio.

> **Martin Murphy, CEO, Syncona Investment Management Limited, said:**
> “Our differentiated model of founding, building and funding businesses has continued
> to gain momentum across the business in the first half. We have delivered excellent
> financial and operational performance, which has translated into strong NAV progression.
> “We have a high-quality portfolio of companies, a leading position in cell and
> gene therapy, and a strategic pool of capital, which underpins our ability to 
> continue to build global leaders in life science to achieve our ambition of delivering
> transformational treatments to patients and capture superior returns for shareholders.”

**Valuation movements in the six months (£m):**

  |

Company

  |

31 Mar 2018

Value (£m)

  |

Net invest-

ment

(£m)

  |

Valuat-

ion change

(£m)

  |

30 Sep 2018 value (£m)

  |

% NAV

  |

Valuat-

ion basis

  |

Fully diluted owner-

ship

stake (%)

  |

Focus area

  |  
 |

Life science companies

  |

 |

 |  
 |

Established

  |  
 |

Blue Earth

  |

186.8

  |

–

  |

44.8

  |

231.6

  |

17

  |

rDCF

  |

89

  |

Advanced diagnostics

  |  
 |

Maturing

  |  
 |

Autolus

  |

85.1

  |

18.1

  |

216.7

  |

319.9

  |

23

  |

Quoted

  |

33

  |

Cell therapy

  |  
 |

Nightstar

  |

124.5

  |

13.8

  |

68.7

  |

207.0

  |

15

  |

Quoted

  |

            38

  |

Gene therapy

  |  
 |

Freeline

  |

36.0

  |

57.5

  |

–

  |

93.5

  |

7

  |

Cost

  |

80

  |

Gene therapy

  |  
 |

Developing

  |  
 |

Gyroscope

  |

11.0

  |

–

  |

–

  |

11.0

  |

1

  |

Cost

  |

78

  |

Gene therapy

  |  
 |

Orbit Biomedical

  |

8.6

  |

–

  |

0.7

  |

9.3

  |

1

  |

Cost

  |

80

  |

Surgical devices

  |  
 |

Achilles

  |

6.6

  |

1.7

  |

–

  |

8.3

  |

1

  |

Cost

  |

69

  |

Cell therapy

  |  
 |

SwanBio

  |

4.9

  |

–

  |

0.4

  |

5.3

  |

0

  |

Cost

  |

72

  |

Gene therapy

  |  
 |

OMass Therapeutics

  |

–

  |

3.5

  |

–

  |

3.5

  |

0

  |

Cost

  |

46

  |

Therapeutics

  |  
 |

Life science investments

  |

 |

 |

 |  
 |

CRT Pioneer Fund

  |

30.8

  |

2.0

  |

–

  |

32.8

  |

2

  |

Adjusted Third-party

  |

N/A

  |

 |

 |  
 |

CEGX

  |

9.8

  |

 |

(3.3)

  |

6.5

  |

0

  |

Adjusted PRI

  |

 |

 |

 |  
 |

Endocyte

  |

9.0

  |

(13.9)

  |

4.9

  |

–

  |

0

  |

Quoted

  |

 |

 |

 |  
 |

Adaptimmune

  |

–

  |

11.6

  |

4.0

  |

       15.6

  |

1

  |

Quoted

  |

 |

 |

 |  
 |

Syncona Collaborations

  |

1.4

  |

–

  |

–

  |

         1.4

  |

0

  |

Cost

  |

 |

 |

 |  
 |

SUB-TOTAL

  |

514.5

  |

94.3

  |

336.9

  |

945.7

  |

68

  |

 |

 |

 |

 |  
 |

 |  
 |

Fund investments

  |

465.1

  |

(81.8)

  |

23.2

  |

406.5

  |

29

  |

 |

 |

 |  
 |

Cash

  |

85.2

  |

31.3

  |

(17.7)

  |

98.8

  |

7

  |

 |

 |

 |  
 |

Other net liabilities

  |

(9.0)

  |

(43.8)

  |

(4.2)

  |

(57.0)

  |

(4)

  |

 |

 |

 |  
 |

TOTAL

  |

1,055.8

  |

–

  |

338.2

  |

1,394.0

  |

100

  |

 |

 |

 |  
 |   |   |   |   |   |   |   |   |   |   |   |

 

 

Share on:
